Long Term Follow-up of Patients With Prosthetic Joint Infection of the Hip Treated at University Hospitals Leuven

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Aug 3, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding and improving the treatment of Prosthetic Joint Infection (PJI) in patients who have had a total hip replacement. PJI can be a serious complication that leads to challenging treatment and longer recovery times. The researchers at University Hospitals Leuven want to gather detailed information about how patients with this infection respond to various treatments. By collecting data from patients treated at their hospital starting January 1, 2022, they aim to provide better insights into treatment outcomes and help inform patients about their chances of recovery.

To be eligible for the trial, participants must be 18 years or older and have been diagnosed with a hip prosthesis infection according to specific guidelines. Unfortunately, those who cannot give their consent or prefer to be treated elsewhere will not be included. Participants can expect to have their treatment experiences monitored closely, which will help the medical team understand what works best for future patients. This trial is important as it aims to address questions about PJI treatment that are difficult to answer through traditional studies, ultimately leading to improved care for those affected by this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • patients diagnosed with PJI of the hip based on EBJIS 2021 criteria
• Exclusion Criteria:
• • Patients unable to provide written informed consent
• • Patients who prefer treatment outside of University Hospitals Leuven
• • Patients with infections of the native hip joint
• • Patients with fracture-related infections (FRI)
• • Patients with uncertain diagnosis of PJI according to the 2021 EBJIS criteria
• • Patient younger than 18 years